‘The Byzantine logic of patent law jurisprudence’: patent protection for dosage regimes revisited

摘要

Legal context The question of whether patent protection extends to treatment or dosage regimes is an important one since patentees are continually seeking to find new and efficient methods of administering known pharmaceutical drugs. The Court of Appeal in Bristol-Myers Squibb seemingly rejected the view that such patents are allowable under the Patents Act 1977.